CardioFocus® Announces Initial Commercial Procedures Following U.S. FDA Approval of HeartLight® X3 System for the Treatment of Atrial Fibrillation

Jun 16, 2020 | EP Lab Digest

CardioFocus, Inc. today announced that the first U.S. patients have been treated commercially with the recently-approved HeartLight® X3 Endoscopic Ablation System.

X